Thank you, Chair.
I think this is an issue where we'll probably find some agreement. The generic pharmaceutical industry in particular was very concerned about the definition of “distinctive” under the proposed legislation. In particular, the concern was related to the issue of consumer confusion, particularly when it comes to medications.
Our amendment proposes to resolve those difficulties because I think the new definition had a number of unintended consequences. Our proposition is to return to that level of certainty that we'd achieved through case law, to return to the former definition of “distinctive”. I believe the government's amendment is almost identical to that, so I hope that we'll actually find some agreement on our amendment.